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Abstract
 
Hairy cell leukemia (HCL) is a chronic B cell malignancy characterized by the diffuse infiltration
of bone marrow and spleen by cells displaying a typical “hairy” morphology. However, the
nature of the HCL phenotype and its relationship to normal B cells and to other lymphoma
subtypes remains unclear. Using gene expression profiling, we show here that HCL displays a
homogeneous pattern of gene expression, which is clearly distinct from that of other B cell
non-Hodgkin lymphomas. Comparison with the gene expression profiles of purified normal
B cell subpopulations, including germinal center (GC), pre-GC (naive), and post-GC (memory)
B cells, shows that HCL cells are more related to memory cells, suggesting a derivation from
this B cell population. Notably, when compared with memory cells, HCL cells displayed a remark-
able conservation in proliferation, apoptosis, and DNA metabolism programs, whereas they
appeared significantly altered in the expression of genes controlling cell adhesion and response
to chemokines. Finally, these analyses have identified several genes that are specifically expressed
in HCL and whose expression was confirmed at the protein level by immunocytochemical
analysis of primary HCL cases. These results have biological implications relevant to the
pathogenesis of this malignancy as well as clinical implications for its diagnosis and therapy.
Key words: DNA microarray • germinal center • hairy morphology • marrow ﬁbrosis • homing
 
Introduction
 
Hairy cell leukemia (HCL) is a chronic B cell lymphopro-
liferative disorder characterized by marked splenomegaly,
pancytopenia, a low number of circulating tumor cells and
diffuse infiltration of the spleen, liver, and BM by tumor
cells exhibiting a hairy appearance and a phenotype different
from that of other B cell lymphomas (1–4). HCL is highly
sensitive to interferon and purine analogue–based treat-
ments (5). Despite the important advances in diagnosis and
therapy, the origin, biological characteristics, and patho-
genesis of HCL remain obscure.
Phenotypically, HCL cells do not clearly resemble any of
the known B cell subpopulation. In the majority of the
cases, leukemic hairy cells bear somatic point mutations in
their Ig variable genes (6, 7), indicating that the cell giving
rise to HCL has transited through the germinal center (GC)
of peripheral lymphoid organs, where it has been exposed
to the hypermutation mechanism (8). Because HCL does
not display significant ongoing somatic hypermutation (6,
7), it has been suggested an origin from a post-GC B cell
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(4). However, an origin within the GC has also been sug-
gested based on the recent finding that a fraction of cases
express multiple and clonally related surface Ig isotypes (6,
7), which is consistent with an arrest at the stage of Ig iso-
type switch (7), which occurs in the GC. Thus, the cell of
origin of HCL is still uncertain.
The uncertainty about the phenotype of HCL is further
fueled by several distinctive properties of these cells, in-
cluding their consistent association with marrow fibrosis,
their hairy appearance, their selective homing to BM, liver,
and spleen with sparing of lymph nodes, and their high
sensitivity to treatment with interferons and purine ana-
logues (1–4). These features suggest that the transformed
phenotype of HCL may involve a complex dependence
from the microenvironment.
To gain insight into these issues, we investigated the
gene expression profiles of 14 cases of HCL using oli-
gonucleotide-based DNA microarrays representative of
 
 
 
12,000 genes. The gene expression profiles of HCL
have been comparatively analyzed with normal and neo-
plastic B cell populations to: (a) identify the cell of origin
of HCL; (b) determine its relationship with other B cell
malignancies; (c) dissect the cellular programs that are al-
tered as a consequence of malignant transformation; and
(d) identify genes and proteins that are specifically ex-
pressed in HCL.
 
Materials and Methods
 
Cases. 
 
The clinico-pathological features of the 14 HCL cases
included in this work are shown in Table SI (available at http://
www.jem.org/cgi/content/full/jem.20031175/DC1). At the
time of sample collection, 10 cases were at diagnosis, whereas the
others had been treated previously with different modalities (Ta-
ble SI), but were off therapy for at least 1 yr (supplemental Mate-
rials and Methods contains a detailed description of sample collec-
tion and preparation, available at http://www.jem.org/cgi/
content/full/jem.20031175/DC1).
This analysis also included 10 cases of B cell chronic lympho-
cytic leukemia (B-CLL) and 36 cases of B cell non-Hodgkin lym-
phomas (B-NHLs), which were classified as follicular lymphomas
(FLs; 
 
n
 
 
 
  
 
6), mantle cell lymphomas (MCLs; 
 
n
 
 
 
  
 
10), Burkitt
lymphomas (BLs; 
 
n
 
 
 
  
 
4), and diffuse large B cell lymphomas
(DLBCLs; 
 
n
 
 
 
  
 
16), according to the REAL and WHO classifica-
tions (3, 4). Except for MCLs, the detailed characterization of
these cases has been reported previously (9). The normal B cell
subpopulations have also been described previously (9, 10). In-
formed consent was obtained from the patients, and the tissue
collection was approved by each institutional ethical committee.
The analyses include the gene expression profiles of four cell lines
derived from multiple myeloma (MM; F24, JJN3, SKMM1, and
SKMM2) and five lymphoblastoid cell lines (CB33, RD, Daikiki,
IARC304, and NC6).
 
Generation of Gene Expression Profiles. 
 
Total RNA was ex-
tracted using the TRIzol reagent (Invitrogen and Life Technolo-
gies) and purified using the Rneasy Kit (QIAGEN). Double-strand
cDNA was generated from 5 
 
 
 
g of total RNA using the Super-
Script Choice System (Invitrogen and Life Technologies) and a
poly-dT oligonucleotide that contains a T7 RNA polymerase ini-
tiation site. The double-strand cDNA was used as template to gen-
 
erate biotinylated cRNA by in vitro transcription using MEGA-
script T7 High Yield Transcription kit (Ambion), biotin-11-CTP,
and biotin-11-UTP (PerkinElmer). The biotinylated cRNA was
purified by the Rneasy Kit (QIAGEN) and fragmented according
to the Affymetrix, Inc. protocol. 15 
 
 
 
g of fragmented cRNA was
hybridized to U95Av2 microarrays (Affymetrix, Inc.). The gene
expression values were determined by software using the Global
Scaling option (Microarray Suite 5.0; Affymetrix, Inc.).
 
Gene Expression Profiles Analysis. 
 
The dendrogram (see Fig.
1) is generated using a hierarchical clustering algorithm based on
the average-linkage method (11, 12). Only genes displaying a
 
 
 
twofold average change in the expression level across the whole
panel were chosen to generate the hierarchical clustering. The ex-
pression value of each selected gene is normalized to have a zero
mean value and unit standard deviation. The distance between
two individual samples is calculated by Pearson distance with the
normalized expression values. To perform the supervised gene ex-
pression analysis (see Fig. 2 A–D, and Figs. 3 and 4), we used the
Genes@Work software platform, which is a gene expression anal-
ysis tool based on the pattern discovery algorithm structural pat-
tern localization analysis by sequential histograms (13, 14). The
classification method used for the cell type classification (see Fig. 2
E) was described previously (9). In brief, the classifier is a scoring
function based on the values of a set of genes (gene cluster), which
are differentially expressed in two sets of cell types and, thus, can
be used for cell type classification. The higher the score, the more
likely it is that a cell type is related to the phenotype set.
 
Immunohistological Stainings. 
 
Immunophenotype was estab-
lished in all cases at the time of diagnosis (Table SII, available at
http://www.jem.org/cgi/content/full/jem.20031175/DC1), and
in most cases, immunohistochemical studies were directly per-
formed on paraffin sections from BM trephines (supplemental
Materials and Methods contains detailed information about the
antibodies used).
Immunostaining procedures were performed as follows. BM
paraffin sections (3–5 
 
 
 
m thick) were attached on silane-coated
slides, dewaxed in three changes of xylene, dehydrated, and sub-
jected to microwaving (750 W 
 
 
 
 three cycles of 5 min each) us-
ing 1 mmol/L EDTA buffer, pH 8.0, as antigen retrieval solution
(15). After microwave heating, sections were allowed to cool at
room temperature for 
 
 
 
20 min, washed with Tris-buffered sa-
line, and stained by the three-stage alkaline phosphatase antialka-
line phosphatase (APAAP) technique (for mAb detection) or the
four-stage APAAP procedure (for polyclonal antibody detection;
references 15, 16). The same staining procedures were used to la-
bel acetone-fixed frozen sections from undecalcified BM tre-
phines or cytospin preparations (17, 18). In all instances, slides
were counterstained for 5 min in hematoxylin and mounted in
Kaiser’s glycerol gelatin.
 
Online Supplemental Material. 
 
Online supplemental material
is available at http://www.jem.org/cgi/content/full/jem.20031175/
DC1. The supplemental material provides: (a) description of the
clinical and pathological features of the HCL cases (Table S1); (b)
immunophenotypical characterization of the cases (Table S2); and
(c) details on sample processing, isolation of CD19
 
+
 
 B cells from
peripheral blood and antibodies used (supplemental Materials and
Methods).
 
Results
 
Gene expression profile analysis was performed on 16
HCL samples obtained from 14 different patients: 11 sam- 
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ples were represented by BM biopsies, 3 by CD19
 
 
 
 puri-
fied B cells from peripheral blood (for 2 samples, the BM
biopsy is also depicted), and 2 by mononucleated cells from
peripheral blood and spleen, respectively. 6 cases of FL, 4
cases of BL, 16 cases of DLBCL, 10 cases of MCL, and 10
cases of B-CLL were included in the comparative analysis.
 
HCL Cells Display a Homogeneous Phenotype Distinct from
Other B Cell Malignancies. 
 
To investigate whether HCL
represents a single disease entity and to determine its rela-
tionship to other B cell malignancies, we used an unsuper-
vised clustering method (Fig. 1; references 11, 12). Fig. 1 A
shows that this method promptly distinguishes HCL from
all other B cell malignancies analyzed. Within the HCL re-
gion, the samples clustered based on their tissue of origin,
namely BM (Fig. 1 A, HCL BM biopsies) or peripheral
blood (including the three purified samples) and spleen.
The BM-derived samples displayed a prominent set of ex-
pressed genes collectively identified as “bone marrow signa-
ture” in Fig. 1 A. To exclude the possibility that the separa-
tion of the HCL samples from the other malignancies was
due to the specific effect of contaminant tissue, the analysis
was performed eliminating the HCL BM biopsies. The re-
Figure 1. Unsupervised hierarchical clustering of gene expression profiles
generated from HCL, non-Hodgkin lymphomas, and B-CLL. Unsuper-
vised analysis was performed on 16 HCL samples obtained from 14 different
patients as follows: 11 samples are BM biopsies (HCL BM biopsies) and 5
samples (HCL) are from different origins, including 3 samples of CD19 
purified cells from peripheral blood (for two of them, the BM biopsy is
also depicted), 1 sample of mononucleated cells from peripheral blood,
and 1 sample of spleen biopsy. The representative panel of B cell malig-
nancies includes 6 cases of follicular lymphoma (FL), 4 cases of Burkitt
lymphoma (BL), 16 cases of diffuse large B cell lymphoma (DLBCL), 10
cases of mantle cell lymphoma (MCL), and 10 cases of B cell chronic
lymphocytic leukemia (B-CLL). The dendrograms are generated using a
hierarchical clustering algorithm based on the average-linkage method. In
the matrix, each column represents a sample and each row represents a
gene. The color scale bar shows the relative gene expression changes normal-
ized by the standard deviation (0 is the mean expression level of a given
gene). (A) The 62 tumor samples (16 HCL, 6 FL, 4 BL, 16 DLBCL, 10
MCL, and 10 B-CLL) are clustered according to their expression of 382
genes. (bone marrow signature) Genes specifically associated to the BM
biopsies. (B) The HCL BM biopsies are not included in this analysis. The
samples are clustered according to their expression of 389 genes.
Figure 2. Relatedness of the gene expression profile of HCL to normal
B cell populations, and LCLs and multiple myeloma (MM) cell lines. A
supervised analysis is used to identify the genes differentially expressed
between two groups of samples. (A) Naive and memory B cells (N & M)
are compared with GC centroblasts and centrocytes. (B) Naive B cells are
compared with memory B cells. (C) EBV-transformed LCLs, representing
immunoblasts, are compared with memory B cells. (D) MM cell lines,
representing transformed plasma cells, are compared with memory B cells.
The expression of the selected genes is investigated in HCL represented
on the right side of each matrix (A–D). The expression of specific GC
(BCL6, CD38, and CD10), naive (CD23), memory B cell (CD27), and
plasma cell (MUM1, CD138, and BLIMP1) markers are highlighted (A–D,
bottom). The supervised analysis is performed using the Genes@Work
software platform. The results of the analysis are shown in the matrices,
where each row represents a gene and each column represents a sample.
Genes are ranked according to the z score (mean expression difference of
the gene between the phenotype group and the control group/standard
deviation). The color change in each row represents the gene expression
relative to the mean across the samples. Values are visualized according
to the scale bar that represents the difference in the   score (expression
difference standard deviation) relative to the mean. (E) A cell-type classi-
fication is used to measure the relatedness of HCL to memory and naive
B cells (M & N) or GC, to memory (M) or naive (N) B cells, to memory
B cells or LCL cell lines, and to memory B cells and MM cell lines. The
gray area marks 95% of confidence: the p-value decreases with increasing
distance from the x axis. 
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sults (Fig. 1 B) show that the remaining HCL samples, in-
cluding the purified samples, still cluster separately from the
other B cell malignancies, indicating that the BM signature
is not responsible for the separate HCL clustering. The
non-HCL B cell malignancies are split into two main
branches according to their GC (FL, BL, and DLBCL) or
non-GC (MCL and B-CLL) origin (9, 19, 20). Overall, this
analysis demonstrates that HCL cases show a largely homo-
geneous phenotype distinct from other B cell malignancies.
 
HCL Are Related to Memory B Cells. 
 
To investigate
the cellular derivation, we analyzed HCL for the expression
of genes that are differentially expressed in purified tonsillar
GC (centroblasts and centrocytes) versus non-GC B cells
(naive and memory), as defined previously by supervised
analysis (10). The analysis indicated that the HCL cases are
significantly more related to memory and naive B cells than
to GC B cells (Fig. 2, A and E). An analogous analysis per-
formed using a profile of genes differentially expressed be-
tween naive and memory B cells showed that hairy leuke-
mic cells are more related to memory B cells than to naive
B cells (Fig. 2, B and E). To further dissect their post-GC
phenotype, we analyzed the HCL profile for genes that are
differentially expressed between EBV-transformed lym-
phoblastic cell lines (LCLs) and MM cell lines as represen-
tative of immunoblasts and plasma cells, respectively. The
results indicate that HCL is more related to LCLs than to
MM cell lines (unpublished data). When the comparison
was performed between LCLs or MM cell lines and mem-
ory B cells, HCL proved to be more related to memory B
cells (Fig. 2, C–E). The expression of specific GC (CD10,
BCL-6, and CD38), naive (CD23), memory B cell
(CD27), and plasma cell (MUM-1, CD138, and BLIMP-1)
markers (Fig. 2 A, B and D, bottom) confirmed the ab-
sence in HCL of GC and plasma cell markers as reported in
previous immunohistochemical papers (3, 4, 21, 22). The
memory B cell marker CD27 (23) is present in most of the
HCL samples, although the expression levels are heteroge-
neous and lower than in memory B cells. Together, these
results indicate that HCL is more related to memory B cells
than to other types of known B cell subpopulations. Thus,
this malignancy may derive from the transformation and
clonal expansion of a memory B cell.
 
HCL Cells Differ from Memory B Cells in the Expression of
Cytokines and Chemokine and Adhesion Receptors. 
 
To fur-
ther investigate the transformed phenotype of HCL vis a
vis the expression of genes that characterize normal mature
B cells, we examined the difference in the pattern of ex-
pression of those genes that are differentially expressed in
naive, memory, and GC cells during the GC transit. These
genes were classified according to relevant functional or
operational categories (10). Consistent with their related-
ness (Fig. 2), HCL showed a gene expression profile largely
superimposable to that of memory B cells in the prolifera-
tion, activation, apoptosis, and DNA metabolism programs
(Fig. 3). Within the proliferation program, the exceptions
of cyclin D1 and CHC1L are notable, which were clearly
up-regulated in HCL. CHC1L, which encodes for a gua-
nine nucleotide exchange factor, and cyclin D1 were also
identified among the genes specifically overexpressed in
HCL cells (see Fig. 4). HCL cells differed from memory B
cells in the expression of various genes encoding signaling
molecules and transcription factors.
Notably, the major differences between HCL and mem-
ory B cells involved the expression of genes encoding cyto-
Figure 3. Analysis in HCL of genes asso-
ciated in normal B cells to the GC transitions.
The genes that are differentially expressed
in naive, memory, and GC B cells during
the GC transit were identified by supervised
analysis. The genes were classified according
to functional categories. The expression of
the transition genes is investigated in HCL
(right, both matrices). For description of the
matrix, see Fig. 2. Genes that show different
expression (at least threefold) between mem-
ory B cells and HCL are indicated. For the
complete list of the genes, GenBank/EMBL/
DDBJ accession nos., and Affymetrix codes,
see Table S3 (available at http://www.jem.org/
cgi/content/full/jem.20031175/DC1). 
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kines and chemokines and their receptors, as well as genes
encoding adhesion molecules. In particular, HCL cells do
not express the TNSF11 gene (known as RANKL) that is
expressed in memory B cells, and it is known to be in-
volved in lymphocyte development and lymph node orga-
nogenesis (24). HCL cells also showed relatively low ex-
pression of the CCR7 gene, which encodes a chemokine
receptor involved in B cell homing (25). Several genes en-
coding adhesion molecules absent in memory B cells are
expressed in HCL cells (GARP, CD9, CD103, and
PCDH9), whereas RNA species expressed in memory B
cells are not expressed in HCL (CD1c and ICAM3), sug-
gesting the acquisition of peculiar adhesion property by
HCL (see Discussion).
 
Identification of Genes Specifically Expressed in HCL. 
 
To
identify genes whose expression is specifically associated
with HCL, we used a supervised analysis comparing HCL
versus various normal B cell subpopulations (naive, GC,
and memory) and major subtypes of B cell malignancies
(6 FL, 4 BL, 16 DLBCL, 10 MCL, and 10 B-CLL). We
used 10 samples of HCL, including 5 BM biopsies and 5
non-BM biopsies (cases 1–4, 6, 8, 11, 12, and the CD19
 
 
 
enriched samples of cases 13 and 14). The analysis identi-
fied 89 genes (7 down-regulated and 82 up-regulated)
Figure 4. Identification of
HCL-specific genes. A super-
vised analysis is performed using
10 samples of HCL (five BM
biopsies and five non-BM samples)
versus the normal B cell subpop-
ulations (CB, CC, N, and M),
different types of B-NHL (FL,
BL, DLBCL, and MCL), and
B-CLL. The B-NHL and B-CLL
tumor samples are the same as
those used in the unsupervised
analysis (Fig. 1). The support
value for the analysis was chosen
as n   n o   2 (no, number of
samples in the phenotype set).
The analysis identified 89 genes
that are differentially expressed in
HCL versus all the other samples.
Gene names are indicated, and
some genes appear more than
once (repeat). For GenBank/
EMBL/DDBJ accession nos. and
Affymetrix codes, see Table S4
(available at http://www.jem.org/
cgi/content/full/jem.20031175/
DC1). 
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that are differentially expressed in HCL cells compared
with the other samples (Fig. 4). Some of these genes were
already known to be expressed in HCL (cyclin D1, FGF2,
and IL-3R
 
 
 
; references 26–28) and served as internal
controls to validate our approach. We observed overex-
pression of cyclin D1 also in MCLs, as a reported hall-
mark of this type of lymphoma. Other known HCL
markers (CD11c, CD68, CD85j, and CD103; references
29–32) were not identified by this type of analysis because
their level of expression in HCL cells were not homoge-
neous and/or they were also expressed in other samples
across the panel.
The expression of only seven genes was found decreased
in HCL cells compared with all the other samples. These
genes included the chemokine receptor CXCR5, involved
in B cell homing (33), and the TNF receptor–associated
factor 5, involved in the signal transduction of TNF-type
receptors, including CD40 and CD27 (34).
Among the newly identified genes that are notably over-
expressed in HCL are (also see Discussion): (a) GAS7, a
growth arrest–specific (Gas) gene (35) that is essential for
neurite outgrowth in cultured cerebellar neurons (overex-
pression of GAS7 in HCL may explain the characteristic
projections of the hairy cells); (b) the FGFR1 receptor that,
together with the previously reported overexpression of its
ligand (FGF2; reference 27), suggests the presence in HCL
of an autocrine loop; (c) the receptor tyrosine kinase FLT3
that is reported to function as a growth factor receptor for
hematopoietic stem and/or progenitor cells (36); and (d)
three different inhibitors of matrix metalloproteinases:
TIMP1 and TIMP4, two secreted tissue inhibitors of me-
talloproteinases, and RECK, a membrane-anchored glyco-
protein that represses synthesis and secretion of metallopro-
teinases (37).
 
Immunocytochemical Validation. 
 
To investigate whether
the up-regulated mRNA levels of HCL-specific genes cor-
respond to elevated levels of the corresponding proteins,
we stained fresh cytospins and/or BM paraffin sections
from patients with HCL (including the cases subjected to
microarray and six additional HCL cases) using monoclonal
and polyclonal antibodies directed against the proteins en-
coded by 22 of the HCL-specific genes.
The expression in HCL cells was confirmed for the fol-
lowing proteins: FGF2 (bFGF), annexin 1, CD135 (FLT3),
Figure 5. (top left, DBA44) BM biopsy from patient
5 showing massive infiltration by DBA44  hairy cells;
the arrow indicates rare residual hemopoietic precursors.
(T) A bone trabecula (APAAP; 800 ). (top middle,
DBA44) Cytocentrifuge preparation (patient 3) showing
strong surface positivity of HCL cells for DBA44 (arrow,
APAAP; 800 ). (Na  CP, I) Cytospin (patient 3).
Positivity for Na  channel, type I, is mainly seen on
the surface membrane (arrow). A negative lymphoid
cell (arrowhead, APAAP; 800 ). (FLT3) Cytospin
(patient 3). Labeling of leukemic cells for FLT3 is
mainly seen on the cell surface (arrow). A negative
normal residual lymphocyte (arrowhead, APAAP;
800 ). (CD63 and SYND-3) Cytospins (patient 3).
Expression of CD63 and Syndecan-3 expression are
mainly cytoplasmic (arrow, microgranular) and perinu-
clear (arrow), respectively (APAAP; 800 ). (FGF2)
BM biopsy (paraffin section) from patient 4. HCL cells
show strong nuclear and cytoplasmic positivity for
FGF2 (arrow, bFGF), whereas residual hemopoietic
precursors are negative (arrowhead, APAAP; 800 ).
(Annexin I) BM biopsy (patient 4). Leukemic cells are
strongly positive for annexin I (arrow). Positivity is
mainly seen in the cytoplasm and surface, whereas nuclei
are negative or faintly positive. An island of annexin
1–negative residual erythroid precursors is shown
(APAAP; 800 ). (TIMP1) Liver biopsy (paraffin section)
from patient 3 showing typical infiltration of hepatic
sinusoids by TIMP1  leukemic hairy cells (APAAP;
800 ). 
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Na
 
 
 
 CP type I (SCN1B), CD63, Syndecan-3, TIMP1
(Fig. 5) as well as IL-3R
 
 
 
, cyclin D1, FGFR1, GAS7,
EPB4.1L2, 
 
 
 
-actin, CPVL, 
 
 
 
-arrestin-2, insulin-like
growth factor binding protein (IGFBP3), MYF6 (Hercu-
lin), protein tyrosine phosphatase receptor 
 
 
 
 (PTPR
 
 
 
),
Synaptotagmin 1, plexin-C1, TIMP4, and 
 
 
 
-2-microglob-
ulin (not depicted). Thus, these results indicate that the
HCL-specific overexpression of genes detected by gene ex-
pression profiling is associated with the overexpression of
the corresponding protein for all genes tested.
 
Discussion
 
This paper has addressed critical questions regarding the
cell of origin and pathogenesis of HCL using gene expres-
sion profiling technology in a panel of 14 cases. This panel
is relatively large considering the difficulties in collecting
HCL samples suitable for gene expression profiling, due to
the very limited availability of HCL cells from the BM (dif-
ficult extraction due to the reticulin fibers), from the pe-
ripheral blood (scarce presence of malignant cells), and
from the spleen (decreasing use of the splenectomy as ther-
apeutic approach; Materials and Methods). Nevertheless,
the panel used here was sufficient to confirm the distinct
phenotype of this disease, to identify its putative cell of ori-
gin, and to discover alterations in cellular programs that
could be of biological and clinical relevance.
 
The Distinct Phenotype of HCL. 
 
HCL has been recog-
nized for a long time as a chronic B cell malignancy with
clinical, morphological, and phenotypic features clearly dis-
tinct from those of other types of B cell lymphomas (3, 4).
The gene expression profile analysis performed here sub-
stantiates this concept by dramatically increasing the num-
ber of traits that characterize the unique HCL phenotype.
In contrast to other B cell malignancies, where the gene
expression profiling has identified unrecognized subsets of
the disease (38), the phenotype of HCL appears to be ho-
mogeneous, suggesting that HCL is a single disease entity
consistent with its homogeneous morphology and clinical
behavior. The characteristic gene expression profile of
HCL may be due to a distinct cellular origin and/or to a
distinct mechanism of transformation.
 
The Cellular Derivation of HCL. 
 
Since its first descrip-
tion, the distinct HCL morphology and phenotype could
not be assigned to a normal B cell developmental stage.
The gene expression analysis shown here indicates that
HCL is more related to memory B cells than to GCs or
naive B cells. Recent findings that draw a relationship be-
tween a tonsillar B cell subset, identified by the phab V-3
antibody, and HCL (39) may be in accordance with the
relationship between HCL cells and memory B cells we
report here. In fact, phab V-3
 
 
 
 B cells do not express GC
B cell markers and CD23, a marker of naive B cells,
whereas they express the memory B cell marker CD27
and display mutated IgV sequences (39), thus, suggesting
that they are memory B cells. As an additional similarity,
the phab V-3
 
 
 
 tonsillar B cells and HCL cells are both
characterized by high level of expression of the CD11c
molecule. Overall, the gene expression profiles together
previous immunophenotypic observations suggest that
HCL cells derive from memory B cells, possibly from a
subset of this population characterized by phab V-3 and
CD11c expression.
 
Pathogenetic Implications. 
 
The notion that HCL may
derive from memory B cells has direct implications for the
pathogenesis of this malignancy. HCL cells typically lack
reciprocal balanced chromosomal translocations, which are
the hallmark of all lymphoid malignancies, with the notable
exception of B-CLLs (40). Intriguingly, B-CLLs also re-
semble memory B cells based on gene expression profiles
(9). Thus, the only two lymphoid malignancies that lack
chromosomal translocations are also both related to mem-
ory B cells. This observation further supports our previ-
ously proposed hypothesis that the lack of chromosomal
translocations may be due to the fact the mechanism that
can generate these aberrations (i.e., Ig VDJ recombination,
class switching, and somatic hypermutation) are switched
off in memory B cells (9). Thus, the pathogenesis of CLL
and HCL may involve genetic lesions, such as the nonran-
dom deletions and amplifications found in these diseases
that do not derive from mistakes of immunoglobulin genes
remodeling mechanism.
 
Functional Alterations in HCL. 
 
This analysis provides
several insights into the functional alterations of HCL. A
careful comparison of HCL with memory B cells revealed a
surprisingly conserved pattern of expression of genes that
regulate functions typically damaged in malignant cells,
such as proliferation and apoptosis. Similarly to memory B
cells, HCL cells appear as largely quiescent cells expressing
genes coding both anti- and proapoptotic molecules. Con-
versely, most of the differences between HCL and memory
B cells involved the expression pattern of cytokines, che-
mokine receptors, and adhesion molecules.
 
Adhesion and Homing of HCL Cells. 
 
Several findings in
this analysis may explain the unique dissemination pattern
of HCL (i.e., involvement of BM, peripheral blood, and
spleen red pulp with sparing of lymph nodes). The ten-
dency of HCL to remain confined in blood-related com-
partments could be at least in part explained by the signifi-
cant up-regulation of three genes (TIMP-1, TIMP-4, and
RECK), all known to counteract the activity of matrix
metalloproteinases, which promote local invasion, extrava-
sation from blood vessels, and metastasis in all types of hu-
man neoplasms (41). Furthermore, the lack of spreading of
HCL cells to lymph nodes can be explained by the down-
regulation of CCR7 (sixfold compared with memory B
cells), a chemokine receptor whose deficiency hampers the
ability of B cells to enter lymph nodes (25). Consistent
with previous immunocytochemical findings (42), our re-
sults show that HCL cells fail to express CXCR5, a che-
mokine receptor required for B cells homing to follicles of
peripheral lymphoid organs (33).
 
Hairy Morphology. 
 
Although recognized as the hall-
mark of HCL, the “hairy” appearance of leukemic cells still 
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remains a feature for which no definitive explanation has
been found. Interaction of the cytoskeleton-binding pro-
tein pp52 (LSP1) with F-actin–rich cytoskeletal arrays in
the surface projections of HCL cells has been proposed as a
mechanism for this property (43). Our results highlight
other HCL-specific molecules that may contribute to the
hairy phenotype, possibly interacting with 
 
 
 
-actin (also up-
regulated in HCL). These molecules are as follows: (a)
Gas7 (Fig. 4), whose ectopic expression induces the forma-
tion of extended cellular processes and dramatic changes in
cell shape by interacting with F-actin (44); and (b)
EPB4.1L2 (Fig. 4), known to play a role in the mainte-
nance of the shape of neuronal cells by interacting with
 
 
 
-actin underneath the plasma membrane (45).
 
Phagocytosis and Macrophage-like Features. 
 
It has been
recognized for a long time that HCL cells have the capacity
to phagocytose latex particles, zymosan, 
 
Staphylococcus au-
reus
 
, and 
 
Pseudomonas aeroginosa
 
 (46, 47), leading to the hy-
pothesis that HCL cells were either B lymphocytes with
phagocytic capabilities (48) or malignant cells of monocytic
origin (49). This phagocytic properties of HCL cells may
be explained by specific up-regulation of annexin 1 (re-
quired for the phagocytic uptake of 
 
Brucella suis
 
 by human
monocytes; reference 50), as well as CD63 (51) and CPVL
(52), two macrophage-associated lysosomal molecules (Fig.
4). We speculate that phagocytosis and expression by HCL
of several macrophage markers (CD11c, CD68, CD63, and
CPVL) may be explained by the apparently abnormal up-
regulation of c-Maf (Fig. 4), a transcription factor whose
deregulated expression can induce macrophage differentia-
tion (53, 54).
 
Marrow Fibrosis. 
 
Another distinctive feature of HCL is
the fine reticulin marrow fibrosis (1–4), which is responsi-
ble for the frequent “dry-tap” at aspiration. This feature is
likely due to the ability of HCL cells to synthesize and bind
to a fibronectin matrix (55, 56), whose production rate is
under control of the autocrine FGF2 secreted by HCL cells
(57). The overexpression of IL-3R
 
 
 
 and FLT3 by HCL
cells (Fig. 4) might play a role in the fibrosis because the
ligands for these two receptors (physiologically present in
the BM stroma microenvironment) are important for adhe-
sion of B cells to fibronectin through activation of the fi-
bronectin receptors VLA4 and VLA5 (58), both known to
be expressed in hairy cells (55, 59).
 
Clinical Implications. 
 
The results herein identify several
antibodies that recognize HCL-specific molecules and,
therefore, may be useful for the diagnosis of HCL. For in-
stance, these reagents may help in the differential diagnosis
between HCL and other borderline B cell chronic lympho-
proliferative disorders (splenic lymphoma with villous lym-
phocytes), and in better defining the nature of the so-called
HCL variant (60). These distinctions have therapeutic im-
plications because HCL and splenic lymphoma with villous
lymphocytes are sensitive to distinct therapeutic regimens
(61). The selective sensitivity of HCL to IFN as compared
with other B cell lymphomas may be explained by the up-
regulation of the TNF receptor, TNFR1, which is likely to
 
potentiate the apoptotic effect of IFN-
 
 
 
–induced TNF-
 
 
 
secretion by HCL cells (62). Finally, HCL-specific cell sur-
face molecules, such as IL-3R
 
 
 
, may represent potential
targets for antibody-mediated immunotherapy, whereas the
abnormal expression of the FLT3 tyrosine kinase receptor
warrants further investigation on the sensitivity of HCL
cells to the currently available inhibitors of FLT3.
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